Page 841 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

Index 819

Consistency, 82t Cutaneous mastocytosis, 397 Cytology, for intestinal tumors, 463
Consolidation therapy, 183 Cutaneous melanoma, 367 Cytopathology
diagnostic, 126–145
Cutaneous papilloma, 356
Consortia group, 345
VetBooks.ir Animal Clinical Investigation (ACI) as, 346 Cutaneous papillomatosis limitations of, 126
Comparative Oncology Trials Consortium
role of, 126
clinical features of, 20
(COTC) as, 345 view of, 21f Cytoplasm, division of, 36
Continuous learning adaptive design, Cutaneous papillomavirus, 353 Cytoplasmic kinase, 258
346–347 Cutaneous squamous cell carcinoma Cytoplasmic pathway
Conventional chemotherapy combined clinical presentation of, 357 phosphatidyl inositol-3 kinase and signal
with metronomic therapies, in canine metastasis of, 357 transducers as, 258–259
osteosarcoma, 544 p53 and, 354 RAS-RAF-MEK-ERK/p38/JNK as, 258
COPLOW. see Comparative Ocular Pathology treatment of, 357 Cytoreductive surgery, 169
Laboratory of Wisconsin Cutaneous T-cell lymphoma, HDAC Cytosine arabinoside (cytarabine),
COR. see Canine orbital rhabdomyosarcomas inhibitors for, 270 188, 193
Core protein, 22 Cyclin, 36–37 Cytotoxic chemotherapeutic, 342–343
Cori cycle hypothesis, 300 G1-S transition regulation of, 261f Cytotoxic T-lymphocyte antigen-4 (CTLA-4),
Coriolis versicolor, 333 Cyclin D-CDK complex, effects of, 36–37 231
Corneal tumor, 675 Cyclin-dependent kinase (CDK) Cytotoxicity, 183
Cortical lysis, in primary bone tumors, G1-S transition regulation of, 261f
528–529 receptor tyrosine kinase signaling and, 259 D
Corticosteroids, prednisone as, 196 regulation of, 36–37 Dacarbazine, 192
Corynebacterium parvum, 236 Cyclin-dependent kinase (CDK) activity, for oral melanoma, 374–375
COTC. see Comparative Oncology Trials 36–37 Dactinomycin (Actinomycin D), 193
Consortium Cyclin-dependent kinase (CDK) inhibitor, Danish Veterinary Cancer Registry (DVCR),
COX. see Cyclooxygenase 36–37 83t
COX-2, in intestinal tumors, 462 Cyclooxygenase (COX), 308f Darier’s sign, 383–384, 384f
Crisis, 46–47 Cyclooxygenase (COX) inhibitor Data Safety and Monitoring Board (DSMB),
Crizotinib (Xalkori), 262 angiogenesis inhibition and, 264 344
Cryoablation, 169 for urinary bladder tumors, 649–650 Deacetylation, 10
Cryosurgery, for ocular tumors, 677–678 Cyclooxygenase-2 (COX-2), in canine Death domain, 39, 39f
Cryptorchid testis, removal of, 170–171 osteosarcoma, 533 DEBs. see Drug-eluting beads
CSA. see Chondrosarcoma Cyclooxygenase-2 (COX-2) expression Debulking, 169
CSC. see Cancer stem cell canine prostate tumor and, 632 Dendritic cell
CT angiography (CTA), 117 canine sinonasal tumors and, 495 histiocytic sarcomas of, 144
CTV. see Clinical target volume Cyclooxygenase-2 inhibitor tumor suppression and, 233–234
Curcumin, 334 for oral melanoma, 375 Dendritic cell leukemia, 792t
Cushing’s syndrome. see for urinary bladder tumors, 651 Dendritic cell vaccination, 240
Hyperadrenocorticism (HAC) Cyclophosphamide 3’-deoxy-3’-fluorothymidine (FLT),
Cutaneous feline mast cell tumor, 393–395 cancer and, 15 119–121
metastasis of, 394 veterinary trials with, 267 Deoxyribonucleic acid (DNA)
treatment of, 394–395 Cystadenocarcinoma, 105f cell damage and, 39
radiation therapy for, 395 Cystadenoma, 598 characteristics of, 146
surgical excision of, 394–395 Cytochemical staining, 129 FeLV-derived, 25
types of, 394 Cytogenetics, 146–147 methylation of, 269–272
Cutaneous histiocytoma, 143–144, 793 Cytokeratin 7, 597 polymerase chain reaction amplification of,
Cutaneous histiocytosis, 792t Cytokeratin 8, 356 146–147
Cutaneous Langerhans cell histiocytosis, 792t, Cytokeratin AE1/AE3, 597 replication/repair, errors in, 7
793–794 Cytokine Deracoxib, 651
Cutaneous lymphoma, HDAC inhibitors for, proteolysis and, 301 Dermal tumor, characteristics of, 141
270 role of, 4–5 Desensitization strategy, for pain
Cutaneous manifestation, of cancer, 104–105 tumor immunotherapy and, 234t–235t management, 298
alopecia, 99b, 105 Cytokinesis, 36 O-Desmethyltramadol (Mi), 295
feline thymoma-associated exfoliative Cytologic specimen Desmin, 597
dermatitis, 99b, 105, 105f cellular arrangement in, 130 Desmoplastic response, 63
necrolytic migratory erythema/superficial examination/description of, 129 Desoxycorticosterone pivalate (DOCP), for
necrolytic dermatitis, 99b, 105 interpretation of adrenal tumors, 574
nodular dermatofibrosis, 99b, 104 basis of, 131–132 Dexmedetomidine, 299t
Cutaneous mast cell tumor confidence in, 132 DHFR. see Dihydrofolate reductase
diagnostic steps for, 388f laboratory shipment of, 131 DI. see Dose intensity
erythema and wheal formation in, 384f nonneoplastic cells/noncellular material in, Diagnostic cytopathology, in clinical oncology,
features of importance and grades for, 68t 129–130 126–145
lymph node aspirate from, 388f Cytologic stains, 127–129 sample collection of, 126–127